Peripheral Vascular Devices – Market Insights – United States

The US PV device market will be primarily driven by product innovation, novel technologies, and adoption of premium solutions. However, barriers such as the push for cost-effective PV interventions and limited availability of certain products will hinder growth going forward.

This Medtech 360 Report provides comprehensive data and analysis on the US PV device market from 2019 through 2034.

The adoption of premium-priced devices will support US PV device market growth.

How is the standard of care changing in the PV device space due to adoption of innovative technologies?

What limitations do new technologies face in terms of approved indications?

To what extent will the limited availability of these technologies in nonhospital settings affect market growth?

The launch of innovative devices for treating infrapop (BTK) lesions will bolster US PV device market growth.

Which device types and technological innovations are being evaluated to address challenges in treating BTK lesions?

How has the entry of BRS affected adoption of endovascular techniques for infrapop indications?

Which competitors stand to benefit from the launch of new devices, and how will this shape the market going forward?

Vessel preparation remains a critical step during interventional endovascular procedures for treating atherosclerosis.

How will adoption of IVL reshape device choices during vessel revascularization procedures? Which devices are seeing increasing adoption?

To what extent are atherectomy procedure volumes affected by current trends?

Will specialty balloons represent a feasible alternative to IVL or atherectomy?

Several key players in the PV device market have expanded their US presence through acquisitions and partnerships.

Which key players are involved in acquisitions and partnerships, and how will these developments impact market share?

How will companies that completed acquisitions adjust their marketing strategies to leverage expanded PV portfolios?